Nifty
Sensex
:
:
17629.50
59141.16
110.05 (0.63%)
417.96 (0.71%)

Pharmaceuticals & Drugs - Global

Rating :
58/99

BSE: 500087 | NSE: CIPLA

954.00
16-Sep-2021
  • Open
  • High
  • Low
  • Previous Close
  •  954.50
  •  964.80
  •  950.20
  •  952.95
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  3574908
  •  34253.60
  •  997.00
  •  706.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 76,934.35
  • 30.27
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 77,288.68
  • 0.52%
  • 4.05

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.72%
  • 4.73%
  • 16.14%
  • FII
  • DII
  • Others
  • 24.82%
  • 15.87%
  • 1.72%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.56
  • 5.89
  • 5.40

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.69
  • 11.07
  • 7.85

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.80
  • 18.99
  • 16.10

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 33.23
  • 34.03
  • 30.44

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.60
  • 3.36
  • 3.21

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.96
  • 16.16
  • 14.55

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Net Sales
5,504.35
4,346.16
26.65%
4,606.45
4,376.19
5.26%
5,168.69
4,371.00
18.25%
5,038.29
4,395.78
14.62%
Expenses
4,158.46
3,297.42
26.11%
3,810.21
3,742.67
1.80%
3,937.81
3,612.67
9.00%
3,861.72
3,486.28
10.77%
EBITDA
1,345.89
1,048.74
28.33%
796.24
633.52
25.69%
1,230.88
758.33
62.31%
1,176.57
909.50
29.36%
EBIDTM
24.45%
24.13%
17.29%
14.48%
23.81%
17.35%
23.35%
20.69%
Other Income
64.93
65.45
-0.79%
60.13
93.18
-35.47%
86.94
72.13
20.53%
53.47
100.52
-46.81%
Interest
29.57
46.00
-35.72%
27.45
53.00
-48.21%
47.92
46.17
3.79%
39.33
46.07
-14.63%
Depreciation
261.11
268.98
-2.93%
285.19
345.80
-17.53%
248.43
277.89
-10.60%
265.06
282.96
-6.33%
PBT
995.52
799.21
24.56%
543.73
327.90
65.82%
1,021.47
506.40
101.71%
925.65
680.99
35.93%
Tax
283.72
227.78
24.56%
128.22
85.59
49.81%
268.96
152.82
76.00%
263.80
200.55
31.54%
PAT
711.80
571.43
24.56%
415.51
242.31
71.48%
752.51
353.58
112.83%
661.85
480.44
37.76%
PATM
12.93%
13.15%
9.02%
5.54%
14.56%
8.09%
13.14%
10.93%
EPS
8.86
7.17
23.57%
5.13
3.05
68.20%
9.28
4.35
113.33%
8.25
5.85
41.03%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
20,317.78
19,159.59
17,131.99
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
Net Sales Growth
16.17%
11.84%
4.70%
7.96%
5.29%
5.88%
19.83%
11.52%
22.88%
17.93%
 
Cost Of Goods Sold
7,831.28
7,351.89
5,991.42
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
Gross Profit
12,486.50
11,807.70
11,140.57
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
GP Margin
61.46%
61.63%
65.03%
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
Total Expenditure
15,768.20
14,975.48
14,025.88
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
Power & Fuel Cost
-
308.26
327.43
335.11
298.82
251.73
245.92
228.28
218.63
233.12
235.35
% Of Sales
-
1.61%
1.91%
2.05%
1.97%
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
Employee Cost
-
3,251.83
3,027.01
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
% Of Sales
-
16.97%
17.67%
17.46%
17.75%
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
Manufacturing Exp.
-
1,206.33
1,372.03
1,284.94
1,220.67
1,192.77
1,023.49
737.11
644.42
541.58
583.18
% Of Sales
-
6.30%
8.01%
7.85%
8.05%
8.29%
7.53%
6.50%
6.33%
6.54%
8.31%
General & Admin Exp.
-
986.01
1,289.13
1,096.50
1,002.43
868.31
845.89
743.46
638.08
496.81
369.85
% Of Sales
-
5.15%
7.52%
6.70%
6.61%
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
Selling & Distn. Exp.
-
1,298.62
1,252.04
1,281.29
1,082.90
1,009.21
818.76
738.87
680.32
466.22
467.61
% Of Sales
-
6.78%
7.31%
7.83%
7.15%
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
Miscellaneous Exp.
-
572.54
766.82
855.40
968.98
645.54
657.29
497.67
441.10
355.12
467.61
% Of Sales
-
2.99%
4.48%
5.23%
6.39%
4.48%
4.83%
4.39%
4.34%
4.29%
2.76%
EBITDA
4,549.58
4,184.11
3,106.11
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
EBITDA Margin
22.39%
21.84%
18.13%
17.53%
16.19%
17.20%
18.24%
19.05%
20.97%
26.55%
23.63%
Other Income
265.47
269.77
369.38
476.57
357.65
228.69
208.21
165.55
265.37
222.14
139.52
Interest
144.27
160.70
197.36
168.43
114.23
159.38
206.63
168.29
145.74
33.91
38.34
Depreciation
1,059.79
1,003.12
1,099.95
1,097.15
949.83
1,322.93
754.22
504.71
372.64
330.48
312.22
PBT
3,486.37
3,290.06
2,178.18
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
Tax
944.70
888.76
631.20
569.53
250.11
179.76
331.59
400.03
463.38
544.31
306.51
Tax Rate
27.10%
27.01%
28.98%
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
PAT
2,541.67
2,417.66
1,593.98
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
PAT before Minority Interest
2,550.96
2,401.30
1,546.98
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
Minority Interest
9.29
16.36
47.00
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
0.00
PAT Margin
12.51%
12.62%
9.30%
9.44%
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
PAT Growth
54.25%
51.67%
3.18%
9.31%
39.46%
-26.14%
13.76%
-13.90%
-9.69%
35.90%
 
EPS
31.57
30.03
19.80
19.19
17.55
12.59
17.04
14.98
17.40
19.26
14.17

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
18,326.53
15,763.00
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
Share Capital
161.29
161.25
161.14
161.02
160.90
160.68
160.59
160.58
160.58
160.58
Total Reserves
18,123.15
15,548.70
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
Non-Current Liabilities
1,660.06
2,972.37
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
1,024.96
824.27
Secured Loans
355.32
304.74
47.70
0.00
0.00
207.00
287.09
317.44
0.00
0.00
Unsecured Loans
847.43
2,064.54
3,782.37
3,662.11
3,645.36
14.88
22.19
0.43
0.55
3.25
Long Term Provisions
116.17
133.27
121.41
137.92
140.52
144.68
1,783.17
1,368.64
713.87
557.78
Current Liabilities
4,591.55
4,393.14
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
Trade Payables
2,066.82
2,281.81
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
979.53
828.36
691.77
Other Current Liabilities
1,093.62
706.65
541.86
647.04
908.95
1,006.14
654.55
408.67
250.89
489.93
Short Term Borrowings
334.73
447.15
486.16
435.87
467.23
4,969.67
1,392.48
910.47
966.38
10.20
Short Term Provisions
1,096.38
957.53
795.50
630.19
426.43
324.42
382.04
264.91
232.00
221.29
Total Liabilities
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
Net Block
9,393.77
9,558.59
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
Gross Block
15,735.87
14,913.62
13,790.31
12,960.01
11,370.70
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
Accumulated Depreciation
6,305.64
5,309.30
4,233.78
3,010.87
1,609.71
799.30
2,731.91
2,179.80
1,707.55
1,410.86
Non Current Assets
11,627.69
11,716.61
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
Capital Work in Progress
968.89
824.53
676.18
981.33
1,682.98
2,060.87
580.90
441.84
377.79
371.17
Non Current Investment
545.43
578.80
490.20
157.66
137.36
176.35
249.76
397.14
415.69
328.59
Long Term Loans & Adv.
645.57
677.08
455.57
514.96
543.67
426.18
1,860.29
1,545.25
971.75
857.53
Other Non Current Assets
74.03
77.61
166.82
255.71
210.06
176.54
168.88
158.89
162.09
46.80
Current Assets
13,209.51
11,706.18
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
Current Investments
2,286.37
1,016.52
2,125.79
1,102.21
837.39
582.34
390.02
311.43
2,116.75
940.52
Inventories
4,669.18
4,377.60
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
Sundry Debtors
3,445.68
3,891.31
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
Cash & Bank
1,401.23
1,003.91
618.81
965.61
638.27
871.40
564.26
175.76
143.01
90.46
Other Current Assets
1,407.05
442.02
415.53
480.20
1,226.01
1,223.17
858.67
630.63
468.31
622.17
Short Term Loans & Adv.
1,031.03
974.82
1,150.95
1,118.93
807.84
780.03
713.07
595.13
463.21
459.94
Net Current Assets
8,617.96
7,313.04
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
Total Assets
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
3,755.20
3,068.45
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
PBT
3,290.06
2,178.18
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
Adjustment
1,130.91
1,365.53
1,268.77
1,293.82
1,374.42
950.85
630.05
552.80
283.82
396.66
Changes in Working Capital
371.66
372.99
-1,063.54
-778.48
235.44
-429.38
-718.61
-561.26
-519.84
199.76
Cash after chg. in Working capital
4,792.63
3,916.70
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,037.43
-848.25
-593.23
-722.04
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,387.18
104.04
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
Net Fixed Assets
-466.10
-450.41
-173.16
-509.84
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
Net Investments
-2,533.43
-1,439.15
-1,239.74
-351.09
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
Others
612.35
1,993.60
-255.78
6.92
-391.07
-6,174.87
427.20
172.71
196.30
-40.51
Cash from Financing Activity
-1,329.90
-2,948.82
-348.72
-385.48
-1,325.68
3,104.06
164.78
-265.63
717.77
-753.17
Net Cash Inflow / Outflow
38.12
223.67
-326.26
223.27
-254.13
322.24
397.06
47.82
52.55
-5.51
Opening Cash & Equivalents
742.38
508.36
853.47
610.35
858.15
545.84
175.76
143.01
90.46
95.97
Closing Cash & Equivalent
793.29
742.38
508.36
853.46
610.35
858.15
564.26
175.76
143.01
90.46

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
226.73
194.85
185.62
175.92
155.15
142.23
133.38
124.79
112.21
95.03
ROA
9.95%
6.56%
6.50%
6.52%
4.97%
7.28%
7.85%
10.49%
13.97%
12.05%
ROE
14.13%
10.09%
10.37%
10.65%
8.72%
12.61%
12.10%
14.89%
18.64%
15.98%
ROCE
17.85%
12.53%
11.94%
10.20%
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
Fixed Asset Turnover
1.84
1.89
1.79
1.25
1.36
1.40
1.26
1.47
1.69
1.61
Receivable days
47.44
54.10
55.36
68.17
61.60
57.62
57.94
58.66
70.11
77.94
Inventory Days
58.49
56.12
61.13
90.71
91.41
100.43
106.36
93.68
92.19
96.16
Payable days
54.19
57.55
59.02
57.37
46.96
51.51
52.17
44.93
48.58
50.51
Cash Conversion Cycle
51.73
52.66
57.47
101.50
106.05
106.55
112.14
107.41
113.72
123.59
Total Debt/Equity
0.10
0.18
0.29
0.29
0.33
0.46
0.16
0.12
0.11
0.00
Interest Cover
21.47
12.04
13.34
15.61
8.67
9.36
10.83
13.90
62.79
38.76

News Update:


  • Cipla enters into joint venture agreement with Kemwell Biopharma
    25th Aug 2021, 15:57 PM

    The JV Company is being incorporated with an objective to enter the respiratory biosimilars space

    Read More
  • Cipla gets USFDA’s final approval for Difluprednate Ophthalmic Emulsion
    12th Aug 2021, 09:17 AM

    Cipla’s Difluprednate Ophthalmic Emulsion 0.05% is AB-rated generic therapeutic equivalent version of Novartis Pharmaceutical Corporation’s Durezol

    Read More
  • Cipla reports 24% rise in Q1 consolidated net profit
    6th Aug 2021, 12:27 PM

    Total income of the company increased by 26.24% at Rs 5569.28 crore for Q1FY22

    Read More
  • Cipla recalls 7,228 bottles of Solifenacin Succinate tablets
    26th Jul 2021, 09:57 AM

    The company is recalling 10 mg, 30-count bottles in the US

    Read More
  • Cipla gets approval to import Moderna's COVID-19 vaccine in India
    29th Jun 2021, 17:01 PM

    Moderna's vaccine will be the fourth COVID-19 jab to be available in India after Covishield, Covaxin and Sputnik

    Read More
  • Cipla gets final approval for Arformoterol Tartrate Inhalation Solution
    23rd Jun 2021, 11:31 AM

    The company has received final approval from the United States Food and Drug Administration

    Read More
  • Cipla’s step-down associate company receives complete response letter from USFDA for IV Tramadol
    15th Jun 2021, 09:32 AM

    Avenue disagrees with the FDA's interpretation of the data in the NDA and intends to continue to pursue regulatory approval for IV tramadol

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.